NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum
The Column Group (TCG) led the round with participation from a select group of investorsPrimary sclerosing cholangitis (PSC) is a...